Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,605,582
  • Shares Outstanding, K 536,440
  • Annual Sales, $ 11,077 M
  • Annual Income, $ 480,000 K
  • 36-Month Beta 1.35
  • Price/Sales 1.90
  • Price/Cash Flow 5.48
  • Price/Book 1.68

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.10 +10.60%
on 02/09/18
47.82 -11.88%
on 01/23/18
-4.50 (-9.65%)
since 01/16/18
3-Month
35.92 +17.32%
on 11/28/17
47.82 -11.88%
on 01/23/18
+4.64 (+12.37%)
since 11/16/17
52-Week
29.39 +43.38%
on 08/15/17
47.82 -11.88%
on 01/23/18
+0.14 (+0.33%)
since 02/16/17

Most Recent Stories

More News
Look for Shares of Mylan Nv to Potentially Pullback after Yesterday's 1.08% Rise

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $41.71 to a high of $42.24. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $41.95...

MYL : 42.14 (+1.18%)
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

MYL : 42.14 (+1.18%)
RDY : 34.74 (+0.03%)
JNJ : 133.15 (+1.46%)
TEVA : 20.90 (+0.43%)
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

MYL : 42.14 (+1.18%)
RDY : 34.74 (+0.03%)
JNJ : 133.15 (+1.46%)
TEVA : 20.90 (+0.43%)
Teva Stock Falls as Novartis Brings Another Copaxone Generic

Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone

MYL : 42.14 (+1.18%)
NVS : 86.91 (+0.27%)
MNTA : 16.05 (-0.31%)
TEVA : 20.90 (+0.43%)
Generic Drugmakers to Dump as Teva's Woes Continue in 2018

The generic industry is facing several challenges pulling down several companies including Teva (TEVA).

MYL : 42.14 (+1.18%)
TLGT : 3.14 (+0.32%)
RDY : 34.74 (+0.03%)
NVS : 86.91 (+0.27%)
TEVA : 20.90 (+0.43%)
Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View

Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.

MYL : 42.14 (+1.18%)
AGN : 164.04 (-0.26%)
MNTA : 16.05 (-0.31%)
TEVA : 20.90 (+0.43%)
Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4

Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

MYL : 42.14 (+1.18%)
MRK : 56.29 (+0.54%)
GILD : 80.70 (-1.04%)
GSK : 37.70 (+1.05%)
Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales

Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.

MYL : 42.14 (+1.18%)
AGN : 164.04 (-0.26%)
SHPG : 134.06 (-0.92%)
SGYP : 2.03 (-3.79%)
SmarTrend Watching for Potential Rebound in Shares of Mylan Nv After 1.50% Loss

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $40.76 to a high of $41.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $41.85 on...

MYL : 42.14 (+1.18%)
Watch for Mylan Nv to Potentially Rebound After Falling 1.50% Yesterday

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $40.76 to a high of $41.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $41.85 on...

MYL : 42.14 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 42.85
1st Resistance Point 42.50
Last Price 42.14
1st Support Level 41.75
2nd Support Level 41.35

See More

52-Week High 47.82
Last Price 42.14
Fibonacci 61.8% 40.78
Fibonacci 50% 38.60
Fibonacci 38.2% 36.43
52-Week Low 29.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.